DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 9,101,663 B2 Yacoby-Zeevi Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 9,101,663 B2 Yacoby-Zeevi Et Al USOO91 01663B2 (12) United States Patent (10) Patent No.: US 9,101,663 B2 Yacoby-Zeevi et al. (45) Date of Patent: *Aug. 11, 2015 (54) CONTINUOUS ADMINISTRATION OF DOPA 5,350,769 A 9, 1994 Kasai et al. DECARBOXYLASE INHIBITORS AND 5,861,423 A * 1/1999 Caldwell et al. .............. 514,351 5,877,176 A 3, 1999 Gross COMPOSITIONS FOR SAME 6,153,615 A 11/2000 Gross 6,166,083 A 12/2000 Barrett et al. (75) Inventors: Oron Yacoby-Zeevi, Bitsaron (IL); 6,245,917 B1 6/2001 Bosch et al. Mara Nemas, Gedera (IL) 6,274,168 B1 8/2001 Addicks et al. 6,348,965 B1 2/2002 Palladino et al. 6,500,867 B1 * 12/2002 Virkki et al. .................. 514,646 (73) Assignee: NeuroDerm, Ltd., Rehovot (IL) 6,620,432 B2 9, 2003 Addicks et al. 6,716.452 B1 4/2004 Piccariello et al. (*) Notice: Subject to any disclaimer, the term of this 6,878,529 B2 4/2005 Harrow et al. patent is extended or adjusted under 35 6,974,591 B2 12/2005 Kendrup et al. U.S.C. 154(b) by 0 days. 7.201923 B1 4/2007 van Lengerich 7,223,776 B2 5/2007 Surivet et al. This patent is Subject to a terminal dis 7,309,719 B1 12/2007 Aomatsu claimer. 7,479,498 B2 1/2009 Keller 7,560, 100 B2 7/2009 Pinchasi et al. 7,589.233 B2 9, 2009 Chandran (21) Appl. No.: 12/961,534 7,709,494 B2 5, 2010 Defossa et al. 7,863,336 B2 1/2011 Yacoby-Zeevi et al. (22) Filed: Dec. 7, 2010 8,058,243 B2 11/2011 Tyers et al. 8,173,840 B2 5, 2012 Chandran (65) Prior Publication Data 8, 193,243 B2 6/2012 Yacoby-Zeevi et al. 8,263,125 B2 9/2012 Vaya et al. US 2011 FO269833 A1 Nov. 3, 2011 2002fOO28799 A1 3/2002 Naylor et al. 2002.00990 13 A1 7/2002 Piccariello et al. 2003/01 19714 A1 6/2003 Naylor et al. Related U.S. Application Data (Continued) (63) Continuation of application No. 12/836,130, filed on Jul. 14, 2010, now Pat. No. 7,863,336, which is a FOREIGN PATENT DOCUMENTS continuation of application No. 12/781,357, filed on CN 101669925 A 3, 2010 May 17, 2010. DE 2838232 A1 3, 1979 (60) Provisional application No. 61/179,511, filed on May (Continued) 19, 2009. OTHER PUBLICATIONS (51) Int. Cl. AOIN33/02 (2006.01) Gordon, M., et al., (2007) “Intravenous Levodopa Administration in A6 IK3I/35 (2006.01) Humans Based on a Two-Compartment Kinetic Model” J. AOIN37/2 (2006.01) Neuroscience Methods 159: 300-307. AOIN 37/44 (2006.01) Hirano, et al., J. Biochem, 2008, vol. 144, No. 3, pp. 363-369. A 6LX3L/95 (2006.01) Mehlisch, et al., J. Clin. Pharmacol., 2002, vol. 42, pp. 904-911. A6 IK3I/24 (2006.01) Movement Disorders “Levodopa” (2002) 17: S23-S37. A6 IK 47/8 (2006.01) Nahata, et al., (2000) “Development of Two Stable Oral Suspensions A6 IK9/00 (2006.01) of Levodopa-Carbidopa for Children with Amblyopia.” J. Pediatric A6 IK3I/2 (2006.01) Opthal. & Strab. 37:333-337. A6 IK3I/98 (2006.01) (Continued) A 6LX3L/277 (2006.01) A6 IK 47/22 (2006.01) (52) U.S. Cl. Primary Examiner — Samira Jean-Louis CPC ............. A61K47/183 (2013.01); A61 K9/0019 (74) Attorney, Agent, or Firm — Goodwin Procter LLP (2013.01); A61 K3I/I2 (2013.01); A61 K 31/198 (2013.01); A61 K3I/277 (2013.01); A61K47/22 (2013.01) (57) ABSTRACT (58) Field of Classification Search Disclosed herein are compositions that include for example USPC .................................. 514/646,565, 567, 534 the arginine salt of carbidopa, and methods for treating neu See application file for complete search history. rological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, (56) References Cited Huntington's disease, Parkinson's like syndrome, PSP. MSA, U.S. PATENT DOCUMENTS ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxi 3,936,495 A 2, 1976 Sullivan, Jr. cation, using Substantially continuous administration of car 4,241,082 A 12/1980 Baba et al. 4.409,233 A 10, 1983 Tsukada et al. bidopa or salt thereof together with administration of 4,642,316 A 2f1987 Fawzi et al. levodopa. 4,684.666 A 8, 1987 HaaS 4,826,875 A 5, 1989 Chies 4,963,568 A 10, 1990 Schoenleber et al. 9 Claims, 18 Drawing Sheets US 9,101,663 B2 Page 2 (56) References Cited Parkinson's Disease.” Expert Review of Neurotherapeutics, 6(10): 1403-1411. U.S. PATENT DOCUMENTS Olanow, C.W. (2008) "Levopoda Dopamine Replacement Strategies in Parkinson's Disease—Future Directions.” Movement Disorders, 2005.0053669 A1 3/2005 Friedl et al. 23:S613-S622. 2005, 0163850 A1 7/2005 Wong et al. Redenti, et al., Journal of Pharmaceutical Sciences, 2001, vol.90, No. 2005/0233945 A1 10/2005 Brown et al. 8, pp. 979-986. 2006,004 1014 A1 2/2006 Naylor et al. Tsumoto, K., et al., (2004) “Role of Arginine in Protein Refolding, 2006, O159751 A1 7/2006 Gogia et al. Solubilization, and Purification.” Biotechnol. Prog. 20:1301-1308. 2006/0241183 A1 10, 2006 Karoun “Duodopa Intestinal Gel.” retrieved from https://www.medicines. 2008/005.1459 A1 2/2008 Nyholm et al. org.uk/emc/medicine/20786/SPC/Duodopa--intestinal+gelicom 2008/0255235 A1 * 10/2008 Segrell .......................... 514,567 position (2013), 7 pages. 2010/0298428 A1 1 1/2010 Yacoby-Zeevi et al. "Pharmacokinetics of Levodopa/Carbidopa Infusion With and With 2012/0115823 A1 5, 2012 Price et al. out Oral Catechol-O-Methyl Transferase (COMT) Inhibitors 2013/0116215 A1 5, 2013 Coma et al. (DuoCOMT),” retrieved from URL://http://clinicaltrials.gov/ct2/ 2013,0123485 A1 5, 2013 Park et al. show/NCT00906828 (2010), 3 pages. 2013/025.305.6 A1 9, 2013 Nemas et al. International Search Report for PCT/IL2010/000400, mailed Jul. 29, 2013/0338143 Al 12/2013 Yacoby-Zeevi et al. 2010, 4 pages. 2014/0051755 A1 2/2014 Yacoby-Zeevi et al. 2014/0249228 A1 9/2014 Yacoby-Zeevi et al. International Search Report for PCT/IL2011/000881, mailed Apr. 3, 2014/0249229 A1 9/2014 Yacoby-Zeevi et al. 2012, 4 pages. 2014/0249230 A1 9/2014 Yacoby-Zeevi et al. International Search Report for PCT/IL2014/050261, mailed May 2014/0249231 A1 9/2014 Yacoby-Zeevi et al. 30, 2014, 5 pages. Nord, M. (2010) The Effect of Peripheral Enzyme Inhibitors on FOREIGN PATENT DOCUMENTS Levodopa Concentrations in Blood and CSF, Movement Disorders, 25(3): 363-367. EP 1077692 A1 2, 2001 Nyholm, D. (2012) "Levodopa Infusion Combined with Entacapone IN 244675 B 12/2010 or Tolcapone in Parkinson Disease: a Pilot Trial.” European Journal IN 251149 B 2, 2012 of Neurology, 19: 820-826. JP 54050700 A 4f1979 Written Opinion of the International Search Authority for PCT/ WO WO-0054773 A1 9, 2000 IL2010/000400 mailed Aug. 29, 2010, 8 pages. WO WO-01 01984 A1 1, 2001 Written Opinion of the International Search Authority for PCT/ WO WO-2005099678 A1 10/2005 IL2011/000881 mailed May 15, 2013, 6 pages. WO WO-2006/006929 A1 1, 2006 Written Opinion of the International Search Authority for PCT/ WO WO-2007.138O86 A1 12/2007 IL2014/050261 mailed May 30, 2014, 6 pages. WO WO-2010, 134074 A1 11, 2010 Yacoby-Zeevi, O., et al. (2010) “Markedly Enhanced Levodopa WO WO-2012/OO6959 A1 1, 2012 Pharmacokinetics from Continuous Subcutaneous Carbidopa WO WO-2012/066538 A1 5, 2012 Administration.” European Journal of Neurology, 17 (Suppl. 3): 52. Martinez et al., “Hypothesis: Can N-Acetylcysteine Be Beneficial in OTHER PUBLICATIONS Parkinson's Disease?”. Life Sciences, 64(15): 1253-1257 (1999). Nutt, J.G. (1997) “Motor Fluctuations. During Continuous Levodopa Pardo et al., “Ascorbic acid protects against levodopa-induced Infusions in Patients with Parkinson's Disease.” Movement Disor neurotoxicity on a catecholamine-rich human neuroblastoma cell ders, 12:285-292. line”. Mov Disord, 8(3):278-284 (1993) Abstract Only. Nyholm, D. (2006) “Enteral Levodopa/Carbidopa Gel Infusion for the Treatment of Motor Fluctuations and Dyskinesias in Advanced * cited by examiner U.S. Patent Aug. 11, 2015 Sheet 1 of 18 US 9,101,663 B2 Fig. 1A 0076+72 200 600 7oosoogoo U.S. Patent Aug. 11, 2015 Sheet 2 of 18 US 9,101,663 B2 Fig. 1B U.S. Patent Aug. 11, 2015 Sheet 3 of 18 US 9,101,663 B2 Fig. 1C 123 s Ooo 110,2030 o' 50 oilre-rrer rtrayers m/z U.S. Patent Aug. 11, 2015 Sheet 4 of 18 US 9,101,663 B2 Fig. 2A U.S. Patent Aug. 11, 2015 Sheet 5 of 18 US 9,101,663 B2 Fig. 2B 00°16)*** *******************&&&&&& 200 250 3OO 350 nz U.S. Patent Aug. 11, 2015 Sheet 6 of 18 US 9,101,663 B2 Fig. 2C © O.8 O.6 0.4 0.2 80 1OO 120 160 180 200 U.S. Patent Aug. 11, 2015 Sheet 7 of 18 US 9,101,663 B2 Fig. 3A E N E. 10 at QP 3. ?ts 1 {o. 3xwk-o-o-o-o-wrotsk M wks-Mo 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 Fig. 3B 1000 - 5 100 d E. 10 s 1 8 12 16 20 24 28 32 36 40 44 48 52 56 6O 64 68 U.S.
Load more

Recommended publications
  • Therapy for Movement Disorders
    Cynthia Comella, MD, FAAN Rush University Medical Center Chicago, IL TREATMENT OF MOTOR SYMPTOMS IN PARKINSON DISEASE Disclosures . Compensation/honoraria for services as a consultant or an advisory committee member: Acadia, Aeon, Allergan, Inc; Impax Pharmaceuticals; Ipsen Biopharmaceuticals, Inc; Medtronic Inc.; Merz Pharmaceuticals; Neurocrine. Royalties: Cambridge, Humana Press; Wolters Kluwer Objectives Treatment of PD . Available treatments for motor PD Treatment of motor symptoms Treatment of motor complications Motor fluctuations Dyskinesia . Overview new therapies in clinical trial Not my objectives Before I came here I was confused about this subject. Having listened to your lecture I am still confused. But on a higher level. Enrico Fermi PD motor symptoms: Therapeutic targets Oertel W, Shulz JB. J Neurochem 2016 . No effective neuroprotective agent . Monotherapy (Efficacious) Levodopa Dopamine agonists: (pramipexole, ropinirole, rotigotine) MAO-B inhibitors: (selegiline, rasagiline) Amantadine (likely) . Motor fluctuations (Efficacious) Efficacious: Dopamine agonists (pramipexole, ropinirole, rotigotine, apomorphine) Levodopa gel intestinal infusions COMT inhibitors (entacapone, tolcapone, opicapone) MAO-B inhibitors (rasagiline, safinamide) Zonisamide Bilateral STN and GPi stimulation . Dyskinesia (Efficacious) Intestinal infusions Amantadine Bilateral STN and GPi stimulation clozapine Fox et al. Mov Disord March 2018 Modest benefit . MAO-B inhibitors (selegiline, rasagiline, safinamide) Modest benefit
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2013/0253056A1 Nemas Et Al
    US 20130253 056A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0253056A1 Nemas et al. (43) Pub. Date: Sep. 26, 2013 (54) CONTINUOUS ADMINISTRATION OF (60) Provisional application No. 61/179,511, filed on May LEVODOPA AND/OR DOPA 19, 2009. DECARBOXYLASE INHIBITORS AND COMPOSITIONS FOR SAME Publication Classification (71) Applicant: NEURODERM, LTD., Ness-Ziona (IL) (51) Int. Cl. A63L/216 (2006.01) (72) Inventors: Mara Nemas, Gedera (IL); Oron (52) U.S. Cl. Yacoby-Zeevi, Moshav Bitsaron (IL) CPC .................................... A6 IK3I/216 (2013.01) USPC .......................................................... 514/538 (73) Assignee: Neuroderm, Ltd., Ness-Ziona (IL) (57) ABSTRACT (21) Appl. No.: 13/796,232 Disclosed herein are for example, liquid aqueous composi (22) Filed: Mar 12, 2013 tions that include for example an ester or salt of levodopa, or an ester or salt of carbidopa, and methods for treating neuro Related U.S. Application Data logical or movement diseases or disorders such as restless leg (63) Continuation-in-part of application No. 12/961,534, syndrome, Parkinson's disease, secondary parkinsonism, filed on Dec. 7, 2010, which is a continuation of appli Huntington's disease, Parkinson's like syndrome, PSP. MSA, cation No. 12/836,130, filed on Jul. 14, 2010, now Pat. ALS, Shy-Drager syndrome, dystonia, and conditions result No. 7,863.336, which is a continuation of application ing from brain injury including carbon monoxide or manga No. 12/781,357, filed on May 17, 2010, now Pat. No. nese intoxication, using Substantially continuous administra 8,193,243. tion of levodopa and/or carbidopa or ester and/or salt thereof.
    [Show full text]
  • Summary of Drug Limitations Mary C
    RON DESANTIS GOVERNOR SUMMARY OF DRUG LIMITATIONS MARY C. MAYHEW SECRETARY **Medications listed in this document may or may not require a prior authorization. Please view the Preferred Drug List at: http://ahca.myflorida.com/Medicaid/Prescribed_Drug/pharm_thera/fmpdl.shtml** Summary of Drug Limitations Abilify (aripiprazole) 2mg, 5mg, 20mg, 30mg tablets Minimum age = 6; Maximum of 1 tablet per day Abilify (aripiprazole) 10mg, 15mg tablets Minimum age = 6; Maximum of 15mg per day for ages = 6 - 11; Maximum of 30mg per day for ages = 12-17 Maximum of 1 tablet per day Abilify (aripiprazole) Discmelt 10mg, 15mg tabs Minimum age = 6; Maximum of 15mg per day for ages = 6 - 11; Maximum of 30mg per day for ages = 12-17; Maximum of 2 tablets per day Abilify (aripiprazole) 1mg/ml solution Minimum age = 6; Maximum of 15ml per day for ages = 6 - 11; Maximum of 30ml per day for ages = 12-17; Maximum of 30ml per day for ages =/> 18 Abilify Maintena (aripiprazole) syringe/vial Minimum age = 18; Maximum of 1 syringe or vial every 28 days Absorica (isotretinoin) 10mg, 20mg, 25mg,30mg, 35mg, & Minimum age = 12 40mg capsules Abstral (fentanyl citrate) sublingual tablets Minimum age = 18; Maximum of 4 sublingual tablets per day Acanya (benzoyl peroxide/clindamycin)Gel, gel pump Minimum Age= 12 Accolate (zafirlukast) tablets Maximum of 3 tablets per day Aciphex (rabeprazole) 5mg, 10mg sprinkle capsules Minimum age = 1; Maximum age = 11; Maximum of 1 capsule per day Aciphex (rabeprazole) 20mg tablets Minimum age = 1; Maximum of 2 tablets per day Actemra (tocilizumab) 80mg/4ml, 200mg/10ml, Minimum age= 2 400mg/20ml Vials, & 162mg/0.9ml Syringe Actimmune (Interferon Gamma-1b) Maximum of 6ml every 28days Actiq (fentanyl citrate) Lozenges Minimum age = 18; Maximum of 4 lozenges per day Activella (estradiol/norethindrone) tablets Minimum age = 18 Updated 02/28/2019 1 RON DESANTIS GOVERNOR SUMMARY OF DRUG LIMITATIONS MARY C.
    [Show full text]
  • Safinamide: an Add-On Treatment for Managing Parkinson's Disease
    Journal name: Clinical Pharmacology: Advances and Applications Article Designation: REVIEW Year: 2018 Volume: 10 Clinical Pharmacology: Advances and Applications Dovepress Running head verso: Müller Running head recto: Safinamide for levodopa/carbidopa-treated PD patients with “off ” episodes open access to scientific and medical research DOI: http://dx.doi.org/10.2147/CPAA.S137740 Open Access Full Text Article REVIEW Safinamide: an add-on treatment for managing Parkinson’s disease Thomas Müller Abstract: Heterogeneous expression of neurotransmitter deficits results from onset and progression of Parkinson’s disease. Intervals, characterized by reappearance of motor and Department of Neurology, St. Joseph Hospital Berlin-Weißensee, Berlin, associated certain nonmotor symptoms, determine the end of good tolerability and efficacy of Germany oral levodopa therapy. These “OFF” states result from levodopa pharmacokinetics and disease progression-related deterioration of the central buffering capacity for fluctuations of dopamine levels. This review discusses safinamide as an add-on therapeutic agent in orally levodopa-treated patients with “OFF” phenomena. Safinamide provided beneficial effects on “OFF” symptoms in pivotal trials with doses of 50 or 100 mg once daily. Safinamide reversibly inhibits mono- amine oxidase B and declines abnormal glutamate release by modulation of potassium- and For personal use only. sodium ion channels. An ideal candidate for combination with safinamide is opicapone. This inhibitor of peripheral catechol-O-methyltransferase supports continuous brain delivery of levodopa and, thus, the continuous dopaminergic stimulation concept. Both compounds with their once-daily application and good tolerability may complement each other by reduction of necessary oral levodopa intakes and “OFF” times. Thus, a promising, future option will be combination of safinamide and opicapone in one formulation.
    [Show full text]
  • Opicapone for the Management of End-Of-Dose Motor Fluctuations in Patients with Parkinson’S Disease Treated with L-DOPA
    Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson’s disease treated with L-DOPA Andrew J. Lees MD1, Joaquim Ferreira MD2, Olivier Rascol MD3, Heinz Reichmann MD,4 Fabrizio Stocchi MD,5 Eduardo Tolosa MD,6 Werner Poewe MD7 1. University College London, Reta Lila Weston Institute, London, UK 2. Hospital de Santa Maria, Centro de Estudos Egas Moniz, Lisbon, Portugal 3. Departments of Clinical Pharmacology and Neurosciences, Clinical Investigation Center CIC 1436, NS-Park/FCRIN network and NeuroToul COEN Center, INSERM, Toulouse University Hospital and Toulouse3 University, Toulouse, France 4. Department of Neurology, Technische Universitaet Dresden, Dresden, Germany 5. Institute of Neurology, IRCCS San Raffaele Pisana, Rome, Italy 6. Neurology Service, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clínic, IDIBAPS, Universitat de Barcelona, Spain. 7. Department of Neurology, Innsbruck Medical University, Innsbruck, Austria Corresponding author Professor Andrew Lees University College London, Reta Lila Weston Institute, 1 Wakefield Street London WC1N 1PJ London, UK Email: [email protected] Direct telephone: + 44 20 7xxxxxxx Fax: +44 20 7xxxxxxx 1 Joaquim Ferreira [email protected] Olivier Rascol [email protected] Eduardo Tolosa [email protected] Fabrizio Stocchi [email protected] Heinz Reichmann [email protected] Werner Poewe [email protected] 2 Summary Introduction: Opicapone is a third generation, highly potent and effective catechol O‑methyltransferase (COMT) inhibitor that optimizes the pharmacokinetics and bioavailability of L- DOPA therapy. Areas covered: In this review, we describe the preclinical and clinical development of opicapone.
    [Show full text]
  • 207145Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 207145Orig1s000 MEDICAL REVIEW(S) Clinical Review Leonard P. Kapcala, M.D. NDA 207145 XADAGO (SAFINAMIDE) CLINICAL REVIEW Application Type NDA Application Number 207145 Priority or Standard Standard Submit Date 9/21/16 Received Date 9/21/16 PDUFA Goal Date 3/21/17 Division / Office DNP/ODE 1 Reviewer Name Leonard P. Kapcala, M.D. Review Completion Date 2/7/17 Established Name SAFINAMIDE (Proposed) Trade Name XADAGO Therapeutic Class Monoamine Oxidase B Inhibitor Applicant Newron Formulation(s) Tablet Dosing Regimen Once daily orally Indication(s) Treatment of signs and symptoms of Parkinson's disease Intended Population(s) Patients with early and advanced Parkinson's disease 1 Reference ID: 4071416 Clinical Review Leonard P. Kapcala, M.D. NDA 207145 XADAGO (SAFINAMIDE) Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT ......................................... 4 1.1 Recommendation on Regulatory Action ............................................................. 4 1.2 Risk Benefit Assessment .................................................................................... 4 1.3 Recommendations for Postmarket Risk Evaluation and Mitigation Strategies ... 5 1.4 Recommendations for Postmarket Requirements and Commitments ................ 5 2 INTRODUCTION AND REGULATORY BACKGROUND ........................................ 5 2.1 Product Information (Based Upon Sponsor Summary) ....................................... 5 2.2 Other Relevant Background Information ...........................................................
    [Show full text]
  • 212489Orig1s000 SUMMARY REVIEW
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 212489Orig1s000 SUMMARY REVIEW Gerald D. Podskalny, DO From Eric Bastings, MD Billy Dunn, MD Subject Joint Summary Review NDA/BLA # and Supplement# NDA 212489 Applicant Neurocrine Biosciences, Inc. Date of Submission 04/26/2019 PDUFA Goal Date 04/26/2020 Proprietary Name Ongentys Established or Proper Name Opicapone Dosage Form(s) 25-mg and 50-mg capsules Adjunctive treatment to levodopa/carbidopa in patients Applicant Proposed with Parkinson’s disease (PD) experiencing “off” Indication(s)/Population(s) episodes Applicant Proposed Dosing 50 mg orally once daily at bedtime. Regimen(s) Regulatory Action Approval Recommended Adjunctive treatment to levodopa/carbidopa in patients Indication(s)/Population(s) (if with Parkinson’s disease (PD) experiencing “off” applicable) episodes. Recommended Dosing 50 mg orally once daily at bedtime. Regimen(s) (if applicable) 1 Reference ID: 4597937 Reference ID: 4597937 1. Benefit-Risk Assessment Benefit-Risk Integrated Assessment Parkinson’s disease (PD) is the second most common neurodegenerative disease, with an estimated prevalence of 930,000 individuals in the United States. PD is caused by progressive loss of dopamine producing neurons in the substantia nigra located in the midbrain. The cardinal motor features of PD are bradykinesia, tremor, rigidity, and postural instability. As PD progresses, it causes increasing motor disability. Medications that replace or enhance the effects of dopamine, such as levodopa, treat the motor aspects of PD and remain the mainstay of treatment. About 5 years after starting treatment with levodopa, many patients develop motor fluctuations (dyskinesia and wearing-off). In advanced PD (approaching 10 years with PD and beyond), patients may develop cognitive impairment, neuropsychiatric symptoms (e.g., hallucinations and impulse control disorders) and impaired autonomic function (e.g., incontinence and orthostatic hypotension).
    [Show full text]
  • A Spanish Consensus on the Use of Safinamide for Parkinson's Disease in Clinical Practice
    brain sciences Review A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in Clinical Practice Javier Pagonabarraga 1,2,3,*, José Matías Arbelo 4,5 , Francisco Grandas 6,7, Maria-Rosario Luquin 8,9, Pablo Martínez Martín 10,11 , Mari Cruz Rodríguez-Oroz 12,13, Francesc Valldeoriola 14,15 and Jaime Kulisevsky 1,2,3,16,17 1 Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain; [email protected] 2 Department of Medicine, Autonomous University of Barcelona, 08193 Barcelona, Spain 3 Centro de Investigación en Red sobre Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain 4 Movement Disorders Unit, Neurology Department, Hospital Universitario San Roque, 35001 Las Palmas, Spain; [email protected] 5 Department of Medicine, Universidad Fernando Pessoa-Canarias, 35450 Las Palmas, Spain 6 Movement Disorders Unit-CSUR, Neurology Department, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain; [email protected] 7 Department of Medicine, Universidad Complutense de Madrid, 28040 Madrid, Spain 8 Movement Disorders Unit, Clínica Universidad de Navarra (CUN), 31008 Pamplona, Spain; [email protected] 9 Navarra Institute for Health Research (IdiSNA), 31008 Pamplona, Spain 10 Instituto de Salud Carlos III, 28029 Madrid, Spain; [email protected] 11 Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain 12 Neurology and Neuroscience Unit, Clínica Universidad de Navarra (CUN), 31008Pamplona,
    [Show full text]
  • Opicapone Capsules for the Treatment of Parkinsons Disease (Pd) in Adult Patients Recommended for Restricted Use (Amber Initiation)
    HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) OPICAPONE CAPSULES FOR THE TREATMENT OF PARKINSONS DISEASE (PD) IN ADULT PATIENTS RECOMMENDED FOR RESTRICTED USE (AMBER INITIATION) Name: generic What it is Indication Date Decision NICE / SMC (trade) decision status Guidance last revised Opicapone 50mg Peripheral, Licensed as adjunctive October 2019 Final NICE TA: not hard capsules selective and therapy to available ® (Ongentys ) reversible catechol- preparations of NICE guidance 0-methyltransferase levodopa/ DOPA for Parkinson’s (COMT) inhibitor decarboxylase disease in adults inhibitors in adult (NG71) patients with SMC not Parkinson's disease recommended and end-of-dose motor AWMSG fluctuations who recommended cannot be stabilised on those combinations HMMC recommendation: Opicapone 50mg capsules, within licensed indications, is recommended for restricted use as AMBER initiation as a second line COMT inhibitor in adult patients with PD with end-of-dose motor fluctuations who are intolerant of entacapone and where the next step of treatment would be the non-oral treatment options or tolcapone. Background Information: Opicapone is the third COMT inhibitor licensed in the UK with the recommended dose of 50 mg as an adjunct to levodopa/DDCI inhibitors. It should be taken once-daily at bedtime, at least one hour before or after levodopa combinations. In certain patients, this may enable a simplified drug regimen which may potentially improve compliance. Some patients taking a complicated PD drug regimen may find it easier to add a single tablet such as opicapone and keep their familiar levodopa doses over the day. In contrast, entacapone has to be taken with each levodopa dose, which may be up to 10 times daily.
    [Show full text]
  • Tolcapone Shared Care Guideline
    Using a printed guideline? Always check you are using the most up to date version. See www.ipnsm.hscni.net Tolcapone Neurology shared care guideline Specialist details Patient identifier Name: Location: Tel: Date: Introduction Licensed indications: Tolcapone is indicated in combination with levodopa/ benserazide or levodopa/carbidopa for use in patients with levodopa-responsive idiopathic Parkinson’s disease and motor fluctuations, who failed to respond to or are intolerant of other catechol-O-methyl transferase (COMT) inhibitors. Adult dosage and administration 100mg three times a day, leave 6 hours between each dose; maximum dose is 200mg three times a day in exceptional circumstances. The first daily dose should be taken at the same time as the levodopa with dopa-carboxylase inhibitor. Patients on higher doses of levodopa (> 600mg daily) or those who had moderate or severe dyskinesia before beginning treatment may require a levodopa dose reduction (specialist should advise). Available as: 100mg tablets Hospital specialist responsibilities Assess patient’s suitability for treatment with tolcapone. Assess patient's current repeat medications for potential significant interactions with the new treatment and discuss with GP if any concerns. Agree shared care with patient’s GP. Provide patient/carer with relevant written information on use, side-effects and need for monitoring of medication. In particular, patients should be informed of the risks of impulse control disorders1 and liver injury2 and advised to seek medical advice immediately. Provide shared care monitoring record booklet and record baseline tests. Baseline tests: LFT, U&E Review results of safety monitoring and request additional tests as required. Monitor disease response to treatment and need to continue therapy – tolcapone should be discontinued if substantial clinical benefits are not seen within 3 weeks of initiation of treatment regardless of dose.
    [Show full text]
  • Parkinson's Disease with End-Of-Dose Motor Fluctuations: Opicapone
    pat hways Parkinson’s disease with end-of-dose motor fluctuations: opicapone Evidence summary Published: 21 March 2017 nice.org.uk/guidance/es9 Key points The content of this evidence summary was up-to-date in March 2017. See summaries of product characteristics (SPCs), British national formulary (BNF), or the MHRA or NICE websites for up-to-date information. Regulatory status: New medicine. Opicapone is a catechol-O-methyl transferase (COMT) inhibitor. It received a European marketing authorisation in June 2016 and was launched in the UK in October 2016. It is licensed for adjuvant therapy to preparations of levodopa/DOPA decarboxylase inhibitor (DDCI) in adults with Parkinson's disease who are experiencing end-of-dose motor fluctuations and cannot be stabilised on those combinations. Overview This evidence summary reviewed 1 randomised placebo- and active-controlled trial in people with Parkinson's disease of at least 3-year duration, who were taking a stable dose of levodopa and experiencing end-of-dose motor fluctuations. Most participants were also taking other arkinsonP 's disease medicines, most commonly a dopamine agonist. There are limited data on the use of opicapone as a first choice adjunct therapy to levodopa. The main clinical benefits of opicapone 50 mg up to 15 weeks were reduced off time of 60.8 minutes and an increase in on time without troublesome dyskinesia of 62.6 minutes, © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- Page 1 of conditions#notice-of-rights). 31 Parkinson’s disease with end-of-dose motor fluctuations: opicapone (ES9) compared with placebo.
    [Show full text]
  • Therapeutic Drug Guidelines for ATCS
    Revision #17 Date: 12-16-2016 Check with FAA flight surgeon to verify that this is the most current revision before using. THERAPEUTIC DRUG GUIDELINES FOR AIR TRAFFIC CONTROL SPECIALISTS Revision #17 Date: 12-16-2016 Check with FAA flight surgeon to verify that this is the most current revision before using. REVISION HISTORY Rev Description of Change Effective Date Posted changes to Accutane and Byetta; clarified nitrates and 1 08-15-2007 anticoagulation; deleted Zelnorm; added entacapone and Chantix 2 Added title page and Revision History page 08-16-2007 On page 3: updated Collective Bargaining Agreement reference and 3 08-29-2007 clarified that this document may be given to ATCSs 4 Clarified use of Optivar - do not instill in the eyes while on duty 08-31-2007 Corrected policy on mefloquine [Lariam]; added atovaquone/proguanil 5 10-05-2007 rMalaronel 6 Added Januvia 10-10-2007 7 Added Cialis 12-04-2007 8 Added aliskiren (Tekturna) 03-03-2008 9 Added mesalamine, including the various brand names 03-05-2008 10 Clarified that insulin pump is acceptable method of insulin delivery 05-19-2008 11 Updated policy on Chantix - it is not aeromedically acceptable 05-21-2008 12 Added levocetirizine (Xyzal) 06-02-2008 Clarified that neither form of oxybutynin (Ditropan and DitropanXL), is 13 05-15-2009 allowed because both can cause sedation similar to Benadryl 14 Article 66, Section 14 (NATCA CBA) annual review 06-30-2011 Corrected dextromethorphan - it is not acceptable due to adverse side 15 07-24-2013 effects. Article 66, Section 14 (NATCA CBA) annual review 16 Updated References; updated overactive bladder medications to indicate all are not acceptable due to new FDA warnings/precautions about 07-31-2013 adverse central nervous system effects including somnolence Revision #17 Date: 12-16-2016 Check with FAA flight surgeon to verify that this is the most current revision before using.
    [Show full text]